9926:HKEXAkeso, Inc. Analysis

Akeso, Inc. (9926.HK) trades at HK$110.2, sitting just below its 50‑day SMA (HK$110.9) but comfortably above the 20‑day SMA (HK$106.0), indicating short‑term momentum while the longer‑term SMA200 (HK$121.2) remains higher, confirming a bearish medium‑term trend. Technical signals are mixed: the MACD histogram is positive (bullish) and the RSI sits at 52.9, suggesting no immediate over‑bought pressure, while volume is increasing and 30‑day volatility is high at 62%, pointing to a choppy price environment. Fundamentally, revenue grew 38% YoY with a robust 79% gross margin, yet operating and net margins are deeply negative, and the forward P/E of 93.6 dwarfs the industry average of 26, flagging significant valuation stretch. The company carries a high debt‑to‑equity ratio of 71% but offsets this with a strong cash position (HK$7.1B) and positive free cash flow (HK$1.2B), mitigating liquidity concerns. Recent material news – the launch of Phase II trials for the bispecific antibody AK139 across seven indications and a new collaboration with Inovio on a glioblastoma combination therapy – adds credible growth catalysts to the pipeline. Analyst consensus is a “strong buy” with a median target of HK$180, implying potential upside of roughly 60% despite the current overvaluation metrics.